| Fund ID | 805-6920379274 |
| Fund type | Hedge Fund |
| 3(c)(1) exclusion | No |
| 3(c)(7) exclusion | Yes |
| Master fund | Yes |
| Feeder fund | No |
| Fund of funds | No |
| Relies on exemption from registration | Yes |
| Annual audit | Yes |
| Prepared per GAAP | Yes |
| Sub-advised | No |
| % of assets independently valued | 100% |
| Owned by the adviser or related persons | 1% |
| Owned by funds of funds | 68% |
| Owned by non-U.S. persons | 29% |
| Fund | Type | Gross assets |
|---|---|---|
| Oncology Impact Fund 2, L.P. | Other Private | $1.01B |
| UBS Oncology Impact Fund L.P. | Other Private | $629.7M |
| Mpm Bioventures 2018, L.P. | Venture Capital | $548.7M |
Mpm Bioimpact Innovations Equities Master, LP reports $113.7 million in gross assets, among the top 40% of private funds by size.
The stated minimum investment is $1 million.
Mpm Bioimpact Innovations Equities Master, LP is managed by Mpm Asset Management LLC.
No. Private funds are not required to publicly disclose performance. Form ADV reports assets, structure, and service providers.